A phase I study of the novel molecularly targeted vascular targeting agent, Exherin (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression
Derek J. Jonker(University of Ottawa), W. P. Peters(Duke University), Rakesh Goel(Ottawa Hospital), C. Cripps(Canadian Partnership Against Cancer), J. Maroun, David J. Stewart(University of Ottawa), Glenwood D. Goss(Ontario Institute for Cancer Research), R. K. Malik(Ottawa Hospital), Julie Wells(Ottawa Hospital), Leonard Avruch
Cited by 6
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
|Journal of Clinical Oncology|1999|960
Wnt Signaling Pathway in Non-Small Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2013|659